+1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Research ArticleOpen Access

Mpviropack Plus: Real Life Study

Volume 3 - Issue 3

Mohamed Baddar4, Taher el Zanaty2, Reda Amer2, Mohsen Salama5, Ramy M Elsharkawy6, Hazem Elbedawei7 , Alaa Osman Elroby8, Osama A Sabry9, Tamer G10 , Hares M11 , Ayman El Badawy13, Nader A Nemr12, Mohamed M Aamer14, Nashaat Hawass12, George Marzouk15, Sherif Ragheb15, Mohamed B Hashem*1 and Esmat G1

  • Author Information Open or Close
    • 1Endemic medicine department, Cairo University, Egypt
    • 2Internal medicine department, Cairo University, Egypt
    • 3Internal medicine department, National Hepatology and Tropical Medicine Research Institute, Egypt
    • 4Ain Shams University, Egypt
    • 5Hepatology Institute, Menoufia, Egypt
    • 6Gastroenterology department, Sohag University, Egypt
    • 7Medical insurance center, Tanta, Egypt
    • 8Gastroenterology and Hepatology department, El fayoum el aam hospital, Egypt
    • 9Internal medicine department, Zagazig hospital, Egypt
    • 10Ain Shams specialized hospital, Damietta, Egypt
    • 11Kafr Saad hospital, Damietta, Egypt
    • 12Endemic and Infectious Diseases Faculty of Medicine Suez Canal University, Egypt
    • 13Internal medicine department, Banha University, Egypt
    • 14Shebin El- Kom teaching hospital, Egypt
    • 15Marcyrl Ph Ind, Egypt

    *Corresponding author: Mohamed B Hashem, Endemic medicine department, Cairo University, Giza, Egypt

Received: March 12, 2018;   Published: April 05, 2018

DOI: 10.26717/BJSTR.2018.03.000918

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


Egypt has the highest prevalence of HCV worldwide. It is estimated to be 7.3% which is considered more than double the global prevalence that is estimated to be 3% according to the World Health Organization (WHO). The main genotype in Egypt is genotype 4 [1]. For many years ago, HCV treatment remained a challenge, where the available regimens were the moderately potent but poorly tolerated combination of pegylated interferon (PegIFN) and ribavirin for 24 or 48 weeks [2]. Using this combination, HCV genotype 4 patients had intermediate SVR rates (50-60%) [3]. Since 2011, multiple new drugs acting on specific enzymatic sites throughout the HCV life cycle were developed (direct acting antiviral drugs DAAs). DAAs are more potent than the INF/RBV with bettersafety profile. DAAs are now widely available worldwide [4].

Abbreviations: WHO: World Health Organization; PegIFN: Pegylated Interferon; DAAs: Direct Acting Antiviral Drugs Daas; AST: Aspartate Transaminase; ALT: Alanine Transaminase; ALB: Albumin; INR: International Normalized Ratio; CBC: Complete Blood Count; AFP: Alpha Feto Protein; FBS: Fasting Blood Sugar; SVR: Sustained Virological Response

Introduction| Patients and Methods| Results| Discussion| Conclusion| References|